News and Events

Dr. Elizabeth Garofalo Joins I-ACT for Children Board of Directors

The Institute for Advanced Clinical Trials for Children (I-ACT for Children) is pleased to announce that Elizabeth Garofalo, MD has joined the Institute as a Member of its Board of Directors. Dr. Garofalo was previously the Senior Vice President at Novartis Pharmaceuticals Corporation with a > 25-year career in drug development.  She has participated in…

I-ACT for Children Appoints Co-Chairs of Its External Advisory Committee

Rockville, MD. The Institute for Advanced Clinical Trials for Children (I-ACT for Children), an independent 501(c)3 non-profit working to advance clinical trials of new medicines and devices for children, announced the appointment of Jonathan Davis, MD, FAAP (Tufts University) and Pamela Simpkins, MBA (Johnson & Johnson) as the leadership of its External Advisory Committee (EAC)….

US Food and Drug Administration Awards I-ACT For Children A Grant For Pediatric Medicines & Devices Network

Rockville, MD The US Food and Drug Administration has awarded the Institute for Advanced Clinical Trials for Children (I-ACT for Children) a grant to improve clinical trials of new drugs and devices for children. The award establishes an alliance among I-ACT for Children and PEDSnet, the James M. Anderson Center for Health Systems Excellence, Critical…

James J Pomfret Joins I-ACT for Children’s Board of Directors

Rockville, MD. The Institute for Advanced Clinical Trials for Children (I-ACT for Children) announced that James J. Pomfret ChFC®, CLU®, AIF®, Managing Director – Investment Officer at Wells Fargo Advisors, has joined the Institute as a member of its Board of Directors. Mr. Pomfret was previously a Budget Analyst with the Social Security Administration, after…

Lisa Benson, BS, CCRP, CRCP joins I-ACT for Children as Vice President, Clinical Research Operations, Quality and Education.

The Institute for Advanced Clinical Trials for Children (aka, I-ACT for Children) is pleased to announce the appointment of Lisa Benson to the position of Vice President, Clinical Research Operations, Quality and Education, beginning June 5. Lisa is a highly-respected research administrator and clinical operations expert.  She comes to I-ACT for Children from the Department…

Pediatric Trials Consortium Reports Completion of Its Objectives Related to I-ACT for Children

This week, Critical Path Institute’s Pediatric Trials Consortium (PTC) reported the completion of its objectives in record time (PTC Deliverables). These includes the posting of the Executive Summary of PTC’s Advisory Report and support for the launch of the Institute for Advanced Clinical Trials for Children, aka I-ACT for Children. The PTC Advisory Report represents the…

Institute for Advanced Clinical Trials for Children Established to Catalyze Innovative Pediatric Therapeutics Clinical Research and Education

New non-profit institute to work with public and private stakeholders to enable research and education on innovative treatments to enhance healthcare for children. (Tucson, AZ) [Regionally: Baltimore, MD], 4/10/2017. Critical Path Institute (C-Path) has established a new 501(c)3 non-profit, the Institute for Advanced Clinical Trials for Children (I-ACT for Children), to support and advance research…

Barry Brooks, JD Joins I-ACT for Children’s Board of Directors

The Institute for Advanced Clinical Trials for Children (I-ACT for Children) welcomes Barry Brooks to its Board of Directors. Mr. Brooks is Partner of Paul Hastings, LLP, an international law firm.  Mr. Brooks is a member of that firm’s Corporate Department, and is the Chair of its 280-attorney New York office.  With a strong presence…

Message from the Chairman…

Welcome to the Institute for Advanced Clinical Trials for Children, aka I-ACT for Children!

Karen King, MS appointed as Vice President, Strategy and Operations, I-ACT for Children

The Institute for Advanced Clinical Trials for Children (I-ACT for Children) welcomes Karen King to its senior leadership team, as Vice President, Strategy and Operations. Ms. King has nearly 20 years of successful experience in the development and commercialization of biopharmaceutical products. She has strong strategic planning, project management, and analytical skills, with specific expertise…